Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Liabilities (2021 - 2025)

Aligos Therapeutics' Total Liabilities history spans 5 years, with the latest figure at $35.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 64.68% year-over-year to $35.0 million; the TTM value through Dec 2025 reached $35.0 million, down 64.68%, while the annual FY2025 figure was $35.0 million, 64.68% down from the prior year.
  • Total Liabilities reached $35.0 million in Q4 2025 per ALGS's latest filing, down from $37.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $99.1 million in Q4 2024 to a low of $31.0 million in Q3 2023.
  • Average Total Liabilities over 5 years is $45.9 million, with a median of $41.8 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: skyrocketed 84.13% in 2024, then crashed 64.68% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $50.6 million in 2021, then fell by 15.49% to $42.8 million in 2022, then skyrocketed by 38.92% to $59.4 million in 2023, then soared by 66.65% to $99.1 million in 2024, then tumbled by 64.68% to $35.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Total Liabilities are $35.0 million (Q4 2025), $37.9 million (Q3 2025), and $32.8 million (Q2 2025).